Letermovir

Letermovir
Clinical data
Other names	AIC246
Routes of; administration	Oral
ATC code	None;
Legal status
Legal status	Investigational;
Identifiers
	IUPAC name {(4S)-8-Fluoro-2-[4-(3-methoxyphenyl)-1-piperazinyl]-3-[2-methoxy-5-(trifluoromethyl)phenyl]-3,4-dihydro-4-quinazolinyl}acetic acid;
PubChem CID	45138674;
ChemSpider	26352849;
UNII	1H09Y5WO1F;
ChEMBL	ChEMBL1241951;
CompTox Dashboard (EPA)	DTXSID40238683 ;
ECHA InfoCard	100.232.644
Chemical and physical data
Formula	C29H28F4N4O4
Molar mass	572.55 g/mol g·mol−1
3D model (JSmol)	Interactive image;
	SMILES COC1=C(C=C(C=C1)C(F)(F)F)N2[C@H](C3=C(C(=CC=C3)F)N=C2N4CCN(CC4)C5=CC(=CC=C5)OC)CC(=O)O;
	InChI InChI=1S/C29H28F4N4O4/c1-40-20-6-3-5-19(16-20)35-11-13-36(14-12-35)28-34-27-21(7-4-8-22(27)30)23(17-26(38)39)37(28)24-15-18(29(31,32)33)9-10-25(24)41-2/h3-10,15-16,23H,11-14,17H2,1-2H3,(H,38,39)/t23-/m0/s1; Key:FWYSMLBETOMXAG-QHCPKHFHSA-N;

Letermovir (INN) is an antiviral drug that is being developed for the treatment of cytomegalovirus (CVM) infections. It has been tested in CMV infected patients with allogeneic stem cell transplants and may also be useful for other patients with a compromised immune system such as those with organ transplants or HIV infections.^[1]

The drug has been granted fast track status by the US Food and Drug Administration (FDA) and orphan drug status by the European Medicines Agency.^[1]

The drug candidate is under development by Merck & Co., Inc as investigative compound MK-8228.^[2]

References

^ ^a ^b "Neues Virostatikum Letermovir" (in German). Deutsche Apothekerzeitung. 2011-08-29.
^ Masangkay, Estel Grace (July 29, 2014). "Merck Kicks Off Phase 3 Study Of CMV Drug Letermovir". Retrieved 8 Oct 2014.

This antiinfective drug article is a stub. You can help Wikipedia by expanding it.

[DAZ-1] "Neues Virostatikum Letermovir" (in German). Deutsche Apothekerzeitung. 2011-08-29.

[2] Masangkay, Estel Grace (July 29, 2014). "Merck Kicks Off Phase 3 Study Of CMV Drug Letermovir". Retrieved 8 Oct 2014.

[1]

[2]